TRISALUS LIFE SCIENCES INC
TLSINASDAQTrading Snapshot
- Day Range
- $4.21 – $4.30
- 52-Week Range
- $2.20 – $7.95
- Volume
- $3.82B
- Avg Volume
- $3.02B
- Shares Outstanding
- 61.6M
- Next Earnings
- Nov 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $45M
- Last Q Revenue
- $11M
- P/E Ratio
- -3.3
- P/S Ratio
- 5.8x
- EPS (TTM)
- $-0.48
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +76.8%
Why Investors Own TLSI
- ✓High-growth profile — revenue up +36.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 26% gross margin and 22% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
TRISALUS LIFE SCIENCES INC
TLSI
StockOtter · stockotter.spaceAbout TRISALUS LIFE SCIENCES INC
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support
The U.S. Food and Drug Administration (FDA) on Wednesday granted 510(k) clearance for TriSalus Life Sciences Inc.'s (NASDAQ:TLSI) TriNav Advance, the newest addition to its Pressure-Enabled Drug Delivery (PEDD) portfolio
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Nasdaq Composite falling over 100 points on Wednesday.
TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard-of-care therapies and its investigational immunoth
TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference.
TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference
TriSalus Life Sciences NASDAQ: TLSI outlined its commercial expansion, product pipeline and clinical-evidence strategy during Canaccord Genuity's Global Growth Conference, with management emphasizing the company's pressu
TriSalus Life Sciences Q2 Earnings Call Highlights
TriSalus Life Sciences NASDAQ: TLSI reported second-quarter revenue of $11.4 million, up 1.7% from $11.2 million a year earlier, as demand for its TriNav pressure-enabled drug delivery system increased. The company reite